Mobile

A Phase 2 Study of Inotuzumab Ozogamicin (CMC-544) in Patients with Indolent (slow-growing) Non-Hodgkin Lymphoma (a type of blood cancer) Who Have Failed Treament with Rituximab and Chemotherapy (a dr...

Mise à jour : Il y a 5 ans
Référence : EUCTR2008-001635-34

A Phase 2 Study of Inotuzumab Ozogamicin (CMC-544) in Patients with Indolent (slow-growing) Non-Hodgkin Lymphoma (a type of blood cancer) Who Have Failed Treament with Rituximab and Chemotherapy (a drug that prevents the growth of tumor cells) or Radioimmunotherapy(a drug that kills tumor cells with radiation)

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate the antitumor activity of inotuzumab ozogamicin in subjects with indolent NHL who have relapsed or are refractory to rituximab and chemotherapy, or anti CD-20 radioimmunotherapy (RIT), as measured by the Overall Response Rate (ORR).

Critère d'inclusion

  • INDOLENT NON-HODGKIN'S LYMPHOMA

Liens